RNA-guided engineered nucleases (RGENs) derived from the prokaryotic adaptive immune system known as CRISPR (clustered, regularly interspaced, short palindromic repeat)/Cas (CRISPR-associated) enable genome editing in human cell lines, animals, and plants, but are limited by off-target effects and unwanted integration of DNA segments derived from plasmids encoding Cas9 and guide RNA at both on-target and off-target sites in the genome. Here, we deliver purified recombinant Cas9 protein and guide RNA into cultured human cells including hard-to-transfect fibroblasts and pluripotent stem cells. RGEN ribonucleoproteins (RNPs) induce site-specific mutations at frequencies of up to 79%, while reducing off-target mutations associated with plasmid transfection at off-target sites that differ by one or two nucleotides from on-target sites. RGEN RNPs cleave chromosomal DNA almost immediately after delivery and are degraded rapidly in cells, reducing off-target effects. Furthermore, RNP delivery is less stressful to human embryonic stem cells, producing at least twofold more colonies than does plasmid transfection.
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The type II CRISPR (clustered, regularly interspaced, short palindromic repeat)/Cas (CRISPR-associated) system is an adaptive immune response in bacteria and archaea, which functions by recognizing and cleaving foreign DNA from phages and plasmids via Cas9 protein and guide RNAs, whose sequences are partially derived from the invaders (Horvath and Barrangou 2010; Wiedenheft et al. 2012) . Recently, we and others exploited this system to develop RNA-guided endonucleases or engineered nucleases (RGENs) that enable targeted genome editing in cultured human cells (Cho et al. 2013a; Cong et al. 2013; Jinek et al. 2013; Mali et al. 2013b ), zebrafish embryos (Hwang et al. 2013) , and bacteria . Since then, RGENs have been successfully used to modify genomes in various species including model organisms (Cho et al. 2013b; Dickinson et al. 2013; Friedland et al. 2013; Gratz et al. 2013; Li et al. 2013a,c; Wang et al. 2013; Sung et al. 2014 ) and plants (Li et al. 2013b; Nekrasov et al. 2013; Shan et al. 2013) , rapidly catching up with their precursors, namely, zinc finger nucleases (ZFNs) (Bibikova et al. 2003; Porteus and Baltimore 2003) and transcription activator-like effector nucleases (TALENs) .
Thus, RGENs are now a new member in the growing family of engineered nucleases . These enzymes cleave chromosomal DNA in cells, producing site-specific double-strand breaks (DSBs), the repair of which via endogenous homologous recombination (HR) or nonhomologous end joining (NHEJ) gives rise to targeted mutagenesis and chromosomal rearrangements. We have developed and improved all of these types of programmable nucleases over the last several years (Kim et al. 2009 (Kim et al. , 2011 Cho et al. 2013a; Kim et al. 2013a; Sung et al. 2013) and reported that the specificity and activity of RGENs are at least on par with those of their precursors. Unlike ZFNs and TALENs, whose DNA-targeting specificities are altered by protein engineering, new RGENs with desired specificities can be prepared simply by replacing guide RNAs. Furthermore, use of in vitro transcribed guide RNAs rather than plasmids that encode them makes this system cloning-free (Cho et al. 2013a) .
For efficient genome editing via RGENs, the successful delivery of guide RNA and Cas9 into cells is essential. In animal experiments, in vitro transcribed Cas9-encoding mRNA or recombinant Cas9 protein can be directly injected into one-cell stage embryos using glass needles to obtain genome-edited animals. To express Cas9 and guide RNA in cultured cells in vitro, typically, plasmids that encode them are transfected via lipofection or electroporation. Unfortunately, use of plasmids is often limited by random integration of all or part of the plasmid DNA into the host genome, a process known as stable transfection. Plasmid DNA can also be inserted at RGEN on-target and off-target sites (Gabriel et al. 2011) . Indeed, we found that at least one out of three large insertions and six out of 26 (23%) small insertions at off-target sites, reported in two recent papers (Cradick et al. 2013; Fu et al. 2013) , were derived from the Cas9-or sgRNA-encoding plasmid (Supplemental Table 1 ). Unwanted insertions of plasmid DNA sequences at off-target sites are difficult to detect and, therefore, more problematic than those at on-target sites. These foreign sequences can cause host immune responses (Hemmi et al. 2000; Wagner 2001) , hampering the use of gene-edited primary or stem cells in cell therapy. In addition, DNA transfection is often stressful to cells. For example, plasmid DNA introduced into cells triggers cyclic GMP-AMP synthase activation (Sun et al. 2013) . Furthermore, prolonged expression of RGENs from plasmid DNA, which can persist in cells for several days posttransfection, can aggravate off-target effects (Gaj et al. 2012) . In line with these concerns, cells transfected with plasmids for biomedical applications or animals and plants derived from DNA-transfected cells are regarded as genetically modified by regulatory authorities (Podevin et al. 2013; Pauwels et al. 2014) , requiring a costly and lengthy regulation procedure for approval in most developed countries. In this study, we show that recombinant Cas9 protein complexed with in vitro transcribed guide RNA can be delivered into cultured human cells, including embryonic stem (ES) cells and fibroblasts, to sidestep many limitations associated with the use of plasmids. RGEN ribonucleoproteins (RNPs) induce small insertions and deletions (indels) at target sites almost immediately after delivery into cells and are degraded rapidly, reducing offtarget effects.
Results
Targeted mutagenesis in human cells using RGEN RNPs Recombinant Cas9 protein was purified from Escherichia coli (Supplemental Fig. 1 ) and complexed with in vitro transcribed single-chain guide RNA (sgRNA) composed of essential portions of target-specific CRISPR RNA (crRNA) and target-independent transactivating crRNA (tracrRNA) or dualRNA that consists of crRNA and tracrRNA. The resulting RNP complex was transfected into the human leukemia K562 cell line via electroporation. At 48 h posttransfection, RGEN-induced indel frequency was measured using T7 endonuclease I (T7E1), which cleaves heteroduplexes formed by the hybridization of mutant and wild-type sequences or two different mutant sequences. The RGEN RNP designed to target the CCR5 gene, which encodes a chemokine receptor that also acts as an HIV co-receptor, was highly active, inducing mutations at frequencies of up to 57% in a dose-dependent manner, comparable to that obtained with plasmids ( Fig. 1A ; Supplemental Fig. 2 ). Small deletions or insertions, signature of error-prone DSB repair via NHEJ, were observed at the target site (Fig. 1B) , reminiscent of those observed with ZFNs and TALENs ). We found that up to sixfold molar excess of sgRNA over Cas9 protein is required to maximize mutation frequencies (Supplemental Fig. 2 ).
To target several other loci in K562, we prepared new RGENs by simply replacing sgRNA in the RNP complex. These RGENs delivered as RNPs were highly active, inducing mutations at frequencies that ranged from 16% to 72% ( Fig. 1C ; Supplemental  Fig. 3 ). The average mutation frequency obtained with RGEN RNPs at eight different sites in K562 cells was 44 6 7% under optimal conditions. Note that T7E1 cannot cleave homoduplexes formed by the hybridization of identical mutant sequences and, therefore, often provides an underestimate of indel frequencies, especially when nucleases are highly active, producing identical mutant sequences .
To rule out the possibility that RGEN RNPs cleave chromosomal DNA after cell lysis and that indels are produced by endogenous proteins associated with NHEJ in the cell lysate under cellfree conditions rather than intracellularly (Budman and Chu 2005) , we transfected Cas9 protein complexed with dualRNA (rather than sgRNA) into K562 cells and isolated single cell-derived clones via limiting dilution. DualRNA was less potent than sgRNA. Mutant clones were obtained at frequencies of 12% (Supplemental Fig. 4 ). Furthermore, no mutations were detected using the T7E1 assay when cells were incubated with RGEN RNPs without electroporation (data not shown). These results show that RGEN RNPs entered cells and cleaved chromosomal DNA, triggering the formation of indels at target sites.
Genome editing in human primary cells and embryonic stem cells
We then investigated whether RGEN RNPs enable efficient genome editing in hard-to-transfect human primary cells such as BJ fibroblasts and pluripotent stem cells such as H9 ES cells. In these cells that are refractory to DNA transfection, RNP delivery via electroporation was at least twofold more efficient than plasmid transfection. Thus, the delivery of the CCR5-specific RGEN RNP induced indels at frequencies of 19% and 23% in BJ fibroblasts and H9 ES cells, respectively, whereas plasmid transfection gave rise to indels at frequencies of 9% and 10%, respectively ( Fig. 2A) . We also tested three other RGEN RNPs in H9 cells and found that the four RGENs induced indels at a frequency of 20 6 3% on average (Fig. 2B) . Notably, RNP delivery was less toxic to ES cells, producing at least twofold more colonies than did plasmid transfection (Fig.  2C) . No apparent changes in the morphology of ES cell colonies were observed after RGEN RNP transfection (Fig. 2D) . Furthermore, all of the colonies expressed alkaline phosphatase, a marker for pluripotency (Fig. 2D) . These results suggest that use of RGEN RNPs rather than plasmids could facilitate isolation of genome-modified clones of ES cells or induced pluripotent stem cells.
Oligonucleotide-directed genome editing via homologydirected repair Next, we investigated whether RGEN RNPs can be co-transfected with homologous donor DNA to achieve genome editing via homologydirected repair. We used single-stranded oligodeoxynucleotides (ssODNs) (Chen et al. 2011 ) rather than gene-targeting vectors or PCR amplicons as donor DNA to avoid the possibility that vectoror amplicon-derived double-strand DNA segments could be inserted randomly in the genome or specifically at RGEN on-or off-target sites. Co-delivery of the AAVS1-specific RNP and an ssODN containing a diagnostic XbaI site gave rise to targeted genome modification in K562 cells at a frequency of 15% measured by XbaI digestion (Fig. 3) . This method can be used to insert small DNA sequences such as loxP or those that encode affinity tags or antigens at pre-determined genomic sites.
Large chromosomal deletions induced by RGEN RNPs
We and others have shown that the repair of two concurrent DSBs produced by ZFNs and TALENs gives rise to targeted chromosomal rearrangements such as deletions, inversions, and translocations (Brunet et al. 2009; Lee et al. 2010 Lee et al. , 2012 Carlson et al. 2012; Kim et al. 2013a) . Likewise, transfection of plasmids that encode Cas9 and sgRNA into human cells can cause chromosomal deletions and translocations in a targeted manner. We tested whether RGEN RNPs can induce large chromosomal deletions in K562 cells. As expected, use of two sgRNAs whose target sites are separated by 10-to 100-kb pairs caused targeted deletions of corresponding chromosomal segments (Fig. 4) , demonstrating that RGEN RNP delivery enables multiplex genome engineering and targeted chromosomal rearrangements.
Reducing off-target effects of RGENs via RNP delivery
RGENs can induce off-target mutations at sites that are highly homologous to on-target sites (Cradick et al. 2013; Fu et al. 2013; Hsu et al. 2013; Pattanayak et al. 2013; Cho et al. 2014) . Off-target DNA cleavages by RGENs can cause unwanted chromosomal rearrangements such as translocations (Cho et al. 2014) . We tested whether RNP delivery could reduce off-target effects of RGENs. To this end, we chose three RGENs that were previously shown to induce off-target mutations at high frequencies in human cells Cho et al. 2014 ) and compared RNP delivery with plasmid transfection. The three RGENs delivered via RNPs were highly active, inducing site-specific mutations at frequencies that ranged from 76% to 79%, and discriminated on-target sites from off-target sites more efficiently than did those delivered via plasmid transfection (Fig. 5) . Thus, no mutations were detected using the T7E1 assay at two off-target sites that differ by 2 nucleotides (nt) from the on-target site, when the RGEN specific to the AAVS1-S3 site was delivered via RNP electroporation. In contrast, the same RGEN delivered via plasmids induced off-target mutations at these sites at frequencies of 6% and 1%, respectively. Importantly, RNP delivery did not sacrifice genome-editing activities at on-target sites, while reducing off-target effects.
We then used deep sequencing to quantify off-target mutations induced by RGEN plasmids and RNPs more accurately. Again, the three RGEN RNPs discriminated on-target sites from off-target sites much more efficiently than did plasmid-driven RGENs. Thus, the RGEN RNP specific to the AAVS1-S3 site induced off-target indels at frequencies of 0.15% and 0.06%. As a result, the ratio of the indel frequency at the on-target site to that at the two off-target sites was 114 and 279, when RNPs were delivered, whereas the ratio was 12 and 22, respectively, when plasmids were transfected, demonstrating 9.5-(114/12) and 13-fold (279/22) differences, respectively, between the two methods. Figure 3 . Homology-directed repair using ssODNs. The 86-mer ssODN includes an XbaI restriction enzyme site, which is absent at the target site, between two short homology arms. PCR amplicons were digested with XbaI in an RFLP assay to detect sequences that resulted from homologydirected repair. 
Kinetics of RGEN RNP-mediated genome editing
We performed a time-course T7E1 assay and Western blotting to understand the molecular basis of the discrepancy between RNP and plasmid delivery. The T7E1 assay showed that RGEN RNPs cleaved chromosomal DNA almost immediately after delivery and that the mutation frequency reached a plateau one day after electroporation (Fig. 6) . In contrast, it took three days to reach an equivalent level of mutations when RGENs were expressed via plasmid transfection. Western blotting analysis showed that Cas9 protein was rapidly degraded in cells when delivered directly: At 24 h post-transfection, Cas9 was barely detected. In contrast, Cas9 protein was expressed from plasmid for several days. Apparently, continuous expression of Cas9 and sgRNA in cells gives rise to the accumulation of off-target mutations. These results are in line with those observed with the direct delivery of ZFNs, which reduces offtarget effects (Gaj et al. 2012) . Unlike ZFN production, however, preparation of new RGENs does not require time-consuming, fastidious, and labor-intensive steps to de novo engineer, express, and purify sequence-specific nucleases (Liu et al. 2014 ).
Discussion
RNA-guided genome editing with the repurposed type II CRISPR/ Cas system has been transforming almost every discipline in the life sciences, biotechnology, and medicine . Compared with ZFNs and TALENs, RGENs are easy to make, affordable, and scalable, lowering barriers to genome editing. However, these programmable nucleases are limited by off-target effects and unwanted integration of plasmid vectors in the genome, unless mRNA or proteins are used. Furthermore, plasmid transfection is often inefficient and stressful to cells. To sidestep these limitations, we delivered RGEN RNPs, rather than plasmids, directly into cells via electroporation and showed that RGEN RNPs enable efficient genome editing even in human primary and ES cells that are refractory to DNA transfection, while reducing off-target effects and avoiding unwanted integration of plasmid DNA in the host genome. In an accompanying paper published in this issue, Ramakrishna et al. (2014) report that a cell-penetrating peptide can be used to deliver both the Cas9 protein and sgRNA into human cells. In principle, Cas9 protein can be replaced with Cas9 mRNA. Unlike mRNA that must be translated in cells, Cas9 protein works immediately after transfection into cells. Furthermore, it is difficult to check the activity of Cas9 mRNA before transfection, whereas the activity of Cas9 protein can be tested easily in vitro before transfection. Cas9 protein can also be used for genotyping of mutations induced by the same RGENs .
Recently, several groups independently reported that RGENs can cause unwanted mutations at off-target sites that differ by up to 5 nt from on-target sites, raising concerns about their specificities (Cradick et al. 2013; Fu et al. 2013; Hsu et al. 2013; Pattanayak et al. 2013) . Off-target effects may result in chromosomal translocations, inactivation of tumor suppressor or other essential genes, and activation of oncogenes. We and others have proposed several methods to reduce or avoid off-target effects of RGENs. First, the concentration of sgRNA and Cas9 can be titrated to improve the ratio of on-target to off-target mutation rates . Unfortunately, titrating RGEN concentrations also reduces on-target mutation frequencies. Second, the use of guide RNA with two additional guanine bases at the 59 end (that do not match with target DNA sequences), termed 59-ggX 20 sgRNA or crRNA, can discriminate on-target sites from off-target sites that differ by 2 nt efficiently without sacrificing on-target activities both in animals (Cho et al. 2013b; Sung et al. 2014 ) and in cell lines (Cho et al. 2013a (Cho et al. , 2014 . Interestingly, truncated sgRNAs can also decrease undesired off-target mutations, improving the specificity of RGENs (Fu et al. 2014) . Third, paired Cas9 nickases (or RGENickases) that generate two adjacent single-strand breaks on opposite DNA strands, producing composite DSBs, double the specificity of RNAguided genome engineering (Mali et al. 2013a; Ran et al. 2013; Cho et al. 2014 ), a strategy adopted from paired zinc finger nickases . Fourth, as shown in this study, RGEN RNPs can be used to reduce off-target effects. Last but not least, one should choose unique target sites that do not have homologous sequences elsewhere in the genome, a strategy we had used to avoid off-target effects of TALENs . A web-based computer program that can be used for the identification of such sites is available ). It may even be possible to combine these approaches to avoid off-target effects completely. Thus, delivery of RGENickase RNPs with two ggX 20 sgRNAs to target a unique sequence in the genome may further reduce off-target effects that persist even with the use of monomeric RGEN RNPs.
In conclusion, RGEN RNPs enable efficient and precise genome editing in diverse human cells including recalcitrant primary and pluripotent stem cells, while avoiding unwanted integration of plasmids and reducing off-target effects. We propose that RGEN RNP delivery will broaden the utility of RNA-guided genome engineering not only in basic research but also in biomedical applications and biotechnology by circumventing regulatory requirements associated with DNA transfection.
Methods
Cell culture K562 (ATCC, CCL-243) cells were grown in RPMI-1640 with 10% FBS and a penicillin/streptomycin mix. BJ (ATCC, CRL-2522) fibroblasts were maintained in alpha-MEM supplemented with 10% FBS, 0.1 mM nonessential amino acids, and a penicillin/streptomycin mix. H9 human ES cells were maintained in DMEM/F12 (Gibco) supplemented with 20% knockout serum replacement (Gibco), 0.1 mM 2-mercaptoethanol (Gibco), 1% nonessential amino acids (Invitrogen), 8 ng/mL fibroblast growth factor-2 (Invitrogen), 50 U/mL penicillin, and 50 mg/mL streptomycin on mitotically inactivated mouse stromal cells.
Recombinant Cas9 protein
Recombinant Cas9 protein was purchased from ToolGen, Inc. or purified from E. coli. The Cas9 DNA sequence was subcloned into pET28-b(+). Recombinant Cas9 protein containing a nuclear localization signal, the HA epitope, and the His-tag at the N terminus was expressed in BL21(DE3) strain, purified using Ni-NTA agarose beads (Qiagen), and dialyzed against 20 mM HEPES pH 7.5, 150 mM KCl, 1 mM DTT, and 10% glycerol. The purified Cas9 protein was concentrated using Ultracel 100K cellulose column (Millipore). The purity and concentration of Cas9 protein were analyzed by SDS-PAGE.
Guide RNA
RNA was in vitro transcribed through run-off reactions by T7 RNA polymerase using the MEGAshortscript T7 kit (Ambion) according to the manufacturer's manual. Templates for sgRNA or crRNA were generated by annealing and extension of two complementary oligonuceotides (Supplemental Table 2 ). Transcribed RNA was purified by phenol:chloroform extraction, chloroform extraction, and ethanol precipitation. Purified RNA was quantified by spectrometry.
Transfection
To introduce DSBs in mammalian cells using an RNP complex, 2 3 10 5 cells were transfected with Cas9 protein (4.5-45 mg) premixed with in vitro transcribed sgRNA (6-60 mg). Cas9 protein in storage buffer (20 mM HEPES pH 7.5, 150 mM KCl, 1 mM DTT, and 10% glycerol) was mixed with sgRNA dissolved in nuclease-free water and incubated for 10 min at room temperature. No more than 4 mL of the RNP mixture was added to 20 mL of the Nucleofection solution. For plasmid-mediated expression of RGENs, 2 3 10 5 cells were co-transfected with 1 mg of Cas9-encoding plasmid and 1 mg of sgRNA-expressing plasmid in K562 and BJ fibroblasts or 2.4 mg of Cas9-encoding plasmid and 1.6 mg of sgRNA-expressing plasmid in H9 hES cells. K562 cells were transfected with the Amaxa SF Cell Line 4D-Nucleofector Kit using Program FF-120 (Lonza), and H9 and BJ cells were transfected with the Amaxa P3 Primary Cell 4D-Nucleofector Kit using Program CB-150 and DT-130, respectively, according to the manufacturer's protocol. Cells were analyzed 2 d after transfection, unless indicated otherwise.
Alkaline phosphatase (AP) staining
H9 human ES cells were fixed using 100% methanol for 10 min and then washed twice with Dulbecco's phosphate buffered saline (DPBS). AP staining was performed using the AP staining kit (Sigma) according to the manufacturer's instructions. Briefly, staining solution was prepared by mixing sodium nitrite solution, FRV-Alkaline solution, and AS-BI alkaline solution. Cells were incubated with the staining solution for 15 min and washed three times with DPBS.
T7E1 assay
Genomic DNA was isolated using a genome isolation kit (Promega) according to the manufacturer's instructions. PCR amplicons including nuclease target sites were generated using the primers listed in Supplemental Table 2 . The T7E1 assay was performed as previously described (Kim et al. 2009 ). Briefly, the PCR amplicons were denatured by heating and annealed to form heteroduplex DNA using a thermocycler and then digested with T7 endonuclease 1 (New England Biolabs) for 20 min at 37°C and then analyzed using agarose gel electrophoresis. For sequencing analysis, PCR products corresponding to genomic modifications were purified and cloned into the T-Blunt vector using the T-Blunt PCR Cloning Kit (SolGent). Cloned products were sequenced using the M13 primer.
RFLP analysis for detection of ssODN-mediated homologous recombination
A total of 2 3 10 5 K562 cells were co-transfected with 15 mg of Cas9 protein mixed with 20 mg of in vitro transcribed sgRNA and 500 pmol of ssODN (Supplemental Table 2 ). After 48 h, genomic DNA was isolated and subjected to PCR amplification with primers that flank the target site (Supplemental Table 2 ). PCR amplicons were digested with XbaI.
Targeted deep sequencing
The on-target and off-target regions were amplified using Phusion polymerase (New England Biolabs) and used for library construction. Equal amounts of the PCR amplicons were subjected to paired-end read sequencing using Illumina MiSeq at Bio Medical Laboratories. Insertions or deletions located around the RGEN cleavage site (3 bp upstream of the PAM) were considered to be the mutations induced by RGENs.
